Antivector and antitransgene host responses in gene therapy

N. R. Hackett, S. M. Kaminsky, D. Sondhi, Ronald Crystal

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Current viral gene therapy vectors effectively transfer genes in vivo at the price of eliciting innate and acquired host responses against the vector and/or transgene. Antigens present in the viral vector and the expression of the transgene both cause cellular and humoral immune responses dependent on the viral vector, the route of administration, and the genotype and infection history of the host. In general, adenoviral vectors cause strong immune responses, which result in only transient expression of the therapeutic gene. Adeno-associated virus and retrovirus vectors elicit weaker immune responses and can therefore result in long-term gene transfer and expression. Methods to avoid host responses, including modification of viral vector and immunosuppression of the host, can increase the longevity and efficiency of gene transfer.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Volume2
Issue number4
Publication statusPublished - 12 Sep 2000
Externally publishedYes

    Fingerprint

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Antibodies
  • Gene therapy
  • Immunity
  • Retrovirus

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this